Download PDF
CC BY-NC-ND 4.0 · Rev Bras Ginecol Obstet 2016; 38(12): 600-608
DOI: 10.1055/s-0036-1597695
Original Article
Thieme-Revinter Publicações Ltda Rio de Janeiro, Brazil

Influence of Dyslipidemia on the Quality of Sexual Life in Women in the Menacme using a Combined Oral Contraceptive

Influência da dislipidemia na qualidade de vida sexual de mulheres na menacme usando contraceptivos orais combinados
Rodolfo Strufaldi
1   Gynecology Discipline, Faculdade de Medicina do ABC, Santo André, SP, Brazil
,
Luciano Melo Pompei
1   Gynecology Discipline, Faculdade de Medicina do ABC, Santo André, SP, Brazil
,
Marcelo Luis Steiner
1   Gynecology Discipline, Faculdade de Medicina do ABC, Santo André, SP, Brazil
,
César Eduardo Fernandes
1   Gynecology Discipline, Faculdade de Medicina do ABC, Santo André, SP, Brazil
› Author Affiliations
Further Information

Publication History

29 May 2016

09 November 2016

Publication Date:
06 February 2017 (online)

   Permissions and Reprints

Abstract

Purpose Female sexual dysfunction is a complex and common condition that affects women, and the relationship between sexual function and dyslipidemia is poorly studied. This study aims to assess this relationship in the reproductive life women in the menacme who use combined oral contraceptives (COCs).

Methods A total of 49 healthy women who were sexually active received COC pills that contained ethinylestradiol 30 mcg (EE30) plus levonorgestrel 150 mcg (LNG150). The women were divided into two groups according to their lipid profiles. Dyslipidemia was defined as a high-density lipoprotein (HDL) level < 50 mg/dL or a low-density lipoprotein (LDL) level > 130 mg/dL. Sexual function was assessed using the Female Sexual Function Index (FSFI) Questionnaire. Lipid and lipoprotein parameters were obtained at baseline and after the sixth cycle.

Results After six cycles of the COCs, the total cholesterol and LDL cholesterol levels in the women with a LDL level > 130 mg/dL decreased by 14.7% and 22.1% respectively. In the women with a HDL level < 50 mg/dL at baseline, the HDL level increased by 15.5% at the end of the study. The arousal and orgasm domains and the FSFI total scores significantly increased in women with and without dyslipidemia. The desire and satisfaction domains increased only in the group without dyslipidemia at the end of the treatment period.

Conclusions The EE30/LNG150 formulation increased the sexual function and it was only positively correlated with the HDL cholesterol level. These data indicated a low correlation between sexual function and the changes in the lipid and lipoprotein metabolism.

Resumo

Objetivo Disfunção sexual feminina é uma condição complexa e comum que acomete as mulheres, e a relação entre a função sexual e a dislipidemia é muito pouco estudada. Este estudo objetivou avaliar esta relação em mulheres na menacme que fazem uso de contraceptivos orais combinados (COCs).

Métodos Um total de 49 mulheres saudáveis com vida sexual ativa receberam pílulas anticoncepcionais contendo etinilestradiol 30 mcg (EE30) associado a levonorgestrel 150 mcg (LNG150). As mulheres foram divididas em dois grupos, de acordo com o perfil lipídico. Dislipidemia foi definida como nível de lipoproteína de alta densidade (HDL) < 50 mg/dL, ou nível de lipoproteína de baixa densidade (LDL) > 130 mg/dL. A função sexual feminina foi avaliada utilizando o questionário de Índice de Função Sexual Feminina (IFSF). O IFSF e os parâmetros lipídicos e lipoproteicos foram obtidos no início e após o sexto ciclo do estudo.

Resultados Após seis ciclos de uso dos COCs, as mulheres com LDL > 130 mg/dL, tiveram redução dos níveis de colesterol total e colesterol LDL de 14,7% e 22,1% respectivamente. Nas mulheres com níveis HDL < 50 mg/dL no momento basal, o nível de HDL aumentou 15,5% ao final do estudo. Os domínios de excitação, orgasmo e os escores totais do IFSF aumentaram significativamente nas mulheres com e sem dislipidemia. Os domínios de desejo e satisfação aumentaram no final do período de tratamento exclusivamente no grupo sem dislipidemia.

Conclusões A formulação EE30/LNG150 aumentou a função sexual das mulheres, sendo positivamente correlata somente com os níveis de colesterol HDL. Estes achados demonstram baixa correlação entre a função sexual e as alterações no metabolismo lipídico e lipoproteico.

Keywords

combined oral contraceptive - quality of sexual life - female sexuality - sexual function questionnaire - dyslipidemia

Palavras-chave

contraceptivo oral combinado - qualidade de vida sexual - sexualidade feminina - questionário de função sexual - dislipidemia
 

  • References

  • 1 Aslan E, Beji NK, Gungor I, Kadioglu A, Dikencik BK. Prevalence and risk factors for low sexual function in women: a study of 1,009 women in an outpatient clinic of a university hospital in Istanbul. J Sex Med 2008; 5 (09) 2044-2052
    CrossrefPubMedGoogle Scholar
  • 2 Veronelli A, Mauri C, Zecchini B. , et al. Sexual dysfunction is frequent in premenopausal women with diabetes, obesity, and hypothyroidism, and correlates with markers of increased cardiovascular risk. A preliminary report. J Sex Med 2009; 6 (06) 1561-1568
    CrossrefPubMedGoogle Scholar
  • 3 Burrows LJ, Basha M, Goldstein AT. The effects of hormonal contraceptives on female sexuality: a review. J Sex Med 2012; 9 (09) 2213-2223
    CrossrefPubMedGoogle Scholar
  • 4 Machado RB, Pompei LM, Giribela A, de Melo NR. Impact of standardized information provided by gynecologists on women's choice of combined hormonal contraception. Gynecol Endocrinol 2013; 29 (09) 855-858
    CrossrefPubMedGoogle Scholar
  • 5 Wierman ME, Nappi RE, Avis N. , et al. Endocrine aspects of women's sexual function. J Sex Med 2010; 7 (1 Pt 2): 561-585
    CrossrefPubMedGoogle Scholar
  • 6 Lachowsky M, Nappi RE. The effects of oestrogen on urogenital health. Maturitas 2009; 63 (02) 149-151
    CrossrefPubMedGoogle Scholar
  • 7 Kaya C, Yilmaz G, Nurkalem Z, Ilktac A, Karaman MI. Sexual function in women with coronary artery disease: a preliminary study. Int J Impot Res 2007; 19 (03) 326-329
    CrossrefPubMedGoogle Scholar
  • 8 Barreiros FA, Guazzelli CA, Barbosa R, Torloni MR, Barbieri M, Araujo FF. Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism. Contraception 2011; 84 (02) 155-159
    CrossrefPubMedGoogle Scholar
  • 9 Tuppurainen M, Klimscheffskij R, Venhola M, Dieben TO. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study. Contraception 2004; 69 (05) 389-394
    CrossrefPubMedGoogle Scholar
  • 10 Heruti R, Arbel Y, Steinvil A. , et al. Pure hypertriglyceridemia might be associated with erectile dysfunction: a pilot study. J Sex Med 2008; 5 (05) 1230-1236
    PubMedGoogle Scholar
  • 11 Salonia A, Giraldi A, Chivers ML. , et al. Physiology of women's sexual function: basic knowledge and new findings. J Sex Med 2010; 7 (08) 2637-2660
    CrossrefPubMedGoogle Scholar
  • 12 World Health Organization [Internet]. Medical eligibility criteria for contraceptive use. Geneva: WHO; 2008 [cited 2016 Feb 10]. Available from: http://apps.who.int/iris/bitstream/10665/69877/1/WHO_RHR_08.19_eng.pdf
    PubMedGoogle Scholar
  • 13 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285 (19) 2486-2497
    CrossrefPubMedGoogle Scholar
  • 14 Rosen R, Brown C, Heiman J. , et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26 (02) 191-208
    CrossrefPubMedGoogle Scholar
  • 15 Thiel RdoR, Dambros M, Palma PC, Thiel M, Riccetto CL, Ramos MdeF. [Translation into Portuguese, cross-national adaptation and validation of the Female Sexual Function Index]. Rev Bras Ginecol Obstet 2008; 30 (10) 504-510
    CrossrefPubMedGoogle Scholar
  • 16 Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005; 31 (01) 1-20
    CrossrefPubMedGoogle Scholar
  • 17 Marniemi J, Mäki J, Maatela J, Järvisalo J, Impivaara O. Poor applicability of the Friedewald formula in the assessment of serum LDL cholesterol for clinical purposes. Clin Biochem 1995; 28 (03) 285-289
    CrossrefPubMedGoogle Scholar
  • 18 Guida M, Di Spiezio Sardo A, Bramante S. , et al. Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners. Hum Reprod 2005; 20 (04) 1100-1106
    CrossrefPubMedGoogle Scholar
  • 19 Dupont WD, Plummer Jr WD. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998; 19 (06) 589-601
    CrossrefPubMedGoogle Scholar
  • 20 Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine aspects of female sexual dysfunction. J Sex Med 2004; 1 (01) 82-86
    CrossrefPubMedGoogle Scholar
  • 21 McCabe M, Althof SE, Assalian P. , et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 2010; 7 (1 Pt 2): 327-336
    CrossrefPubMedGoogle Scholar
  • 22 Esposito K, Ciotola M, Maiorino MI. , et al. Hyperlipidemia and sexual function in premenopausal women. J Sex Med 2009; 6 (06) 1696-1703
    CrossrefPubMedGoogle Scholar
  • 23 Greco T, Graham CA, Bancroft J, Tanner A, Doll HA. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception 2007; 76 (01) 8-17
    CrossrefPubMedGoogle Scholar
  • 24 van Rooijen M, von Schoultz B, Silveira A, Hamsten A, Bremme K. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. Am J Obstet Gynecol 2002; 186 (01) 44-48
    CrossrefPubMedGoogle Scholar
  • 25 Dragoman M, Curtis KM, Gaffield ME. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes. Contraception 2016; 94 (03) 280-287
    CrossrefPubMedGoogle Scholar
  • 26 Wallwiener CW, Wallwiener LM, Seeger H, Mück AO, Bitzer J, Wallwiener M. Prevalence of sexual dysfunction and impact of contraception in female German medical students. J Sex Med 2010; 7 (06) 2139-2148
    CrossrefPubMedGoogle Scholar
  • 27 Warnock JK, Clayton A, Croft H, Segraves R, Biggs FC. Comparison of androgens in women with hypoactive sexual desire disorder: those on combined oral contraceptives (COCs) vs. those not on COCs. J Sex Med 2006; 3 (05) 878-882
    CrossrefPubMedGoogle Scholar
  • 28 Panzer C, Wise S, Fantini G. , et al. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction. J Sex Med 2006; 3 (01) 104-113
    CrossrefPubMedGoogle Scholar
  • 29 Caruso S, Iraci Sareri M, Agnello C. , et al. Conventional vs. extended-cycle oral contraceptives on the quality of sexual life: comparison between two regimens containing 3 mg drospirenone and 20 µg ethinyl estradiol. J Sex Med 2011; 8 (05) 1478-1485
    CrossrefPubMedGoogle Scholar
  • 30 Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. Eur J Contracept Reprod Health Care 2013; 18 (01) 27-43
    CrossrefPubMedGoogle Scholar
  • 31 Strufaldi R, Pompei LM, Steiner ML. , et al. Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels. Contraception 2010; 82 (02) 147-154
    CrossrefPubMedGoogle Scholar
  • 32 Lopez LM, Grimes DA, Chen-Mok M, Westhoff C, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2010; (07) CD008452
    PubMedGoogle Scholar
  • 33 Esposito K, Ciotola M, Giugliano F. , et al. Association of body weight with sexual function in women. Int J Impot Res 2007; 19 (04) 353-357
    CrossrefPubMedGoogle Scholar
  • 34 Ponholzer A, Temml C, Rauchenwald M, Marszalek M, Madersbacher S. Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women?. Int J Impot Res 2008; 20 (01) 100-104
    CrossrefPubMedGoogle Scholar
  • 35 Yaylali GF, Tekekoglu S, Akin F. Sexual dysfunction in obese and overweight women. Int J Impot Res 2010; 22 (04) 220-226
    CrossrefPubMedGoogle Scholar
  • 36 Kadioglu P, Yetkin DO, Sanli O, Yalin AS, Onem K, Kadioglu A. Obesity might not be a risk factor for female sexual dysfunction. BJU Int 2010; 106 (09) 1357-1361
    CrossrefPubMedGoogle Scholar